HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse transcriptase (NNRTI)-based first-line antiretroviral therapy. We evaluated HIV-1 seroconversions in MTN-020/ASPIRE for selection of drug resistance and evaluated the genetic basis for observed reductions in susceptibility to DPV.
November 2021
Click for full info +Full Info:
Resource Type:
Database
Journal Article
Journal Article
Resource
Citation:
A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse transcriptase (NNRTI)-based first-line antiretroviral therapy. We evaluated HIV-1 seroconversions in MTN-020/ASPIRE for selection of drug resistance and evaluated the genetic basis for observed reductions in susceptibility to DPV.
Authors: Parikh, UM; Penrose, KJ ; Heaps, AL ; Halvas, EK ; Goetz, BJ; Gordon, KC ; Hardesty, R ; Sethi, R ; Schwarzmann, W ; Szydlo, DW ; Husnik, MJ ; Chandran, U ; Palanee-Phillips, T ; Baeten, JM ; Mellors, JW ; the MTN-020 Study Team
Health Risks(s):
- HIV
Product type(s):
- IVR
Topic(s):
- DrugInteractions
- Development
Region(s)
- Africa